PD-L1 (Programmed Death-Ligand 1) serves as a target for immune checkpoint inhibition in cancer therapy, preventing cancer cells from evading immune system attacks by binding to the PD-1 receptor on T cells. The gene discussed is CD274; the disease is cancer.